Screening new compounds to reverse gene signatures in IPF lungs
Official title: Screening of novel compounds through the reversal of gene expression in idiopathic pulmonary fibrosis
Funded at Henry Ford Health + Michigan State University Health Sciences · NIH-11494256 · Data updated 2026-11-12
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Henry Ford Health + Michigan State University Health Sciences NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project start | April 1, 2025 |
| Project end | March 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $521,483 |
| NIH project number | 5R61HL177451-02 |
| Project ID | NIH-11494256 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with IPF or related fibrosing lung conditions could be relevant once therapies advance to human testing.
✕Less likely to help
Participants in early lab studies may not directly benefit until later clinical steps.
What this research studies
This project aims to identify and test compounds that can flip disease-related gene signals in IPF-affected lung tissue. Using advanced AI and single-cell data, researchers will pinpoint targets in small airways and evaluate how compounds affect these targets. The work focuses on translating molecular findings into potential therapies that could slow or reverse fibrosis in patients with IPF.
Why it matters
Potential benefit: If successful, this work could pave the way for treatments that halt or reverse lung fibrosis and improve survival and quality of life for IPF patients.
How similar studies have gone: Previous IPF drugs slow progression but do not reverse fibrosis; this approach seeks a novel reversal of disease signals.
Where this research is happening
-
Henry Ford Health + Michigan State University Health Sciences
East Lansing, United States Active
Researchers
- Principal investigator: Li, Xiaopeng — Henry Ford Health + Michigan State University Health Sciences
- Study coordinator: Li, Xiaopeng
Related research
Other NIH-funded projects on the same topics.
-
Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis
A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).
-
Unraveling IPF subtypes to guide prognosis and therapy
This grant aims to identify different IPF subtypes in the lung to improve how we predict outcomes and tailor treatments for people with IPF.
-
Novel antibody therapy to treat idiopathic pulmonary fibrosis
A small business gig is developing a targeted antibody drug (VSR-H5) to treat idiopathic pulmonary fibrosis in patients, aiming for better safety and effectiveness than current medicines.
-
Repurposing Vonoprazan as an inhaled therapy for IPF
A high-profile NIH grant is testing whether an existing drug, vonoprazan, can be inhaled to slow or reverse lung fibrosis in people with idiopathic pulmonary fibrosis (IPF).
-
Proteomic profile of IPF progression to help tailor treatments
A study will look for blood protein patterns that predict how IPF lung disease will progress in patients.
-
Adrenergic Nerves and Noradrenaline in Lung Fibrosis
A physician-scientist-in-training at Yale seeks to build a patient-focused research program on how nerve signals and adrenaline affect lung scarring in IPF.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.